Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07487597
EARLY_PHASE1

Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors

Sponsor: TCRCure Biopharma Ltd.

View on ClinicalTrials.gov

Summary

This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of functionally enhanced ALPP-targeted engineered T Cells (Herein referred to as Enhanced ALPP CAR-T) in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.

Official title: A Single-Arm, Single-Center, Open-Label Pilot Study of Functionally Enhanced ALPP-Targeted Engineered T Cells for Patients With ALPP-Positive Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-02-28

Completion Date

2029-02-28

Last Updated

2026-03-23

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

Enhanced ALPP CAR-T treatment

Enhanced ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.

Locations (1)

The Jinling Hospital

Nanjing, Jiangsu, China